{"id":390753,"date":"2017-12-26T00:00:00","date_gmt":"2017-12-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0017-2017-biopharma-non-small-cell-lung-cancer-unmet-need-us-eu-2017\/"},"modified":"2026-03-31T10:49:00","modified_gmt":"2026-03-31T10:49:00","slug":"unneon0017-2017-biopharma-non-small-cell-lung-cancer-unmet-need-us-eu-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0017-2017-biopharma-non-small-cell-lung-cancer-unmet-need-us-eu-2017\/","title":{"rendered":"Non-Small-Cell Lung Cancer | Unmet Need | US\/EU | 2017"},"content":{"rendered":"<p>Despite the wide range of treatment options available, metastatic non-small-cell lung cancer (<abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>) remains a major cause of cancer-related death. For patients with metastatic (<i><abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr><\/i>&#8211; and <i><abbr title=\"anaplastic lymphoma kinase\">ALK<\/abbr><\/i>-negative\/unknown) <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>, chemotherapy is still a mainstay of treatment. However, immune checkpoint inhibitors (Opdivo, Keytruda, and most recently Tecentriq) are revolutionizing the treatment algorithm for this subpopulation. As this market segment continues to evolve at a rapid pace, drug manufacturers must understand the unmet needs associated with the treatment of metastatic <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> to identify the opportunities for drug development. We focus on this commercially important subpopulation and assess how current therapies perform on key drug attributes and how these attributes affect medical oncologists\u2019 prescribing decisions. We identify potential hidden opportunities and which emerging therapies (if any) could capitalize upon them. Furthermore, we use conjoint analysis to determine attribute and price trade-offs that surveyed medical oncologists are willing to make when considering treatment options for metastatic <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> and simulate the share of preference and likelihood to prescribe of different target product profiles.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for metastatic (<i><abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr><\/i>&#8211; and <i><abbr title=\"anaplastic lymphoma kinase\">ALK<\/abbr><\/i>-negative\/unknown) <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>?<\/li>\n<li>What attributes are key influences, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for metastatic (<i><abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr><\/i>&#8211; and <i><abbr title=\"anaplastic lymphoma kinase\">ALK<\/abbr><\/i><i>&#8211;<\/i>negative\/unknown) <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in metastatic (<i><abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr><\/i>&#8211; and <i><abbr title=\"anaplastic lymphoma kinase\">ALK<\/abbr><\/i>-negative\/unknown) <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to <abbr title=\"United States\">U.S.<\/abbr> and European medical oncologists for a hypothetical new metastatic (<i><abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr><\/i>&#8211; and <i><abbr title=\"anaplastic lymphoma kinase\">ALK<\/abbr><\/i>-negative\/unknown) <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> drug?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 <abbr title=\"United States\">U.S.<\/abbr> and 30 European medical oncologists fielded in December 2016.<\/p>\n<p><strong>Key companies:<\/strong> Bristol-Myers Squibb, Merck &#038; Co., Eli Lilly &#038; Co., Roche\/Genentech<\/p>\n<p><strong>Key drugs:<\/strong> Opdivo, Keytruda, Alimta, Avastin<\/p>\n","protected":false},"template":"","class_list":["post-390753","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390753\/revisions"}],"predecessor-version":[{"id":576757,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390753\/revisions\/576757"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}